To read the full story, subscribe or sign in.

Seikagaku, Ono Pharma plan next steps for arthritis drug after positive Japan phase III results

June 16, 2020

HONG KONG – Japan’s Seikagaku Corp. is contemplating the next move for its ONO-5704/SI-613 (diclofenac etalhyaluronate), a treatment for arthritis that it is co-developing with fellow Japanese company Ono Pharmaceutical Co. Ltd.

BioWorld BioWorld Asia Clinical Inflammatory Japan

Today's news in brief

BioWorld

BioWorld briefs for July 25, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 25, 2025.

CHMP rejects Sarepta’s Elevidys, changes mind on Lilly’s Kisunla

BioWorld

After a tough few weeks for Sarepta Therapeutics Inc., the EMA dealt another blow on July 25, announcing it will not be approving the Duchenne muscular dystrophy...

Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

BioWorld

The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...

Illustration of Microglia cells (red) in Alzheimer´s disease

Two cancer drugs combined modify Alzheimer’s disease in mice

BioWorld

Current treatments for Alzheimer’s disease have limited effects. While they can slow cognitive decline or alleviate symptoms, they do not reverse this complex...